Product Overview
Dragon Pharma packages this material as a single lyophilised vial totalling 10 mg of two peptides. The first half is CJC-1295 without DAC, also written Mod GRF 1-29, a growth hormone releasing hormone analogue. The second is ipamorelin, a selective growth hormone secretagogue that acts on the ghrelin receptor. Because the two halves use different receptors, the usual rationale is that one prepares the pituitary and the other triggers the release, and ipamorelin is the popular partner precisely because it is described as not raising cortisol or prolactin.
The word DAC carries real weight. CJC-1295 with the drug affinity complex has an albumin-binding anchor that stretches its action across days, which is a different product with a different injection rhythm, sold separately as CJC-1295 DAC 5mg. The version in this vial has no anchor, so its half-life is about 30 minutes after a subcutaneous dose and it produces short pulses rather than a plateau. The ipamorelin half runs for roughly two hours, which is human pharmacokinetic data rather than an estimate. That spread, 30 minutes against 2 hours, is the single most useful number on the card, because it explains why a once-daily routine cannot hold anything steady.
Proportions are worth checking before anything else. In the sister pack from the same group the split is 5 mg plus 5 mg, a clean 1:1. For this Dragon Pharma vial the total is 10 mg and the exact split is set by the label on the vial; the ratio is not confirmed in the sources used here, so it is not assumed. No approved dosage form exists for either half as a blend, and no study of this fixed combination was found. Related single-compound options in the section are Ipamorelin 5mg, Tesamorelin 5mg and the other blend, Ipamorelin and Tesamorelin 10mg.
Blend Reconstitution and Research Amounts
There is no human schedule for the mixture. The table gives the dilution maths for a 10 mg vial and the per-injection amounts found in vendor conventions for each half separately, which is a weaker standard of evidence and is labelled as such.
| Solvent | Bacteriostatic water added down the wall of the vial; do not shake the powder |
| Two millilitres per vial | Five mg per ml, so a ten-unit draw of 0.1 ml is 500 mcg of the mixture |
| Five millilitres per vial | Two mg per ml, which puts a ten-unit draw at 200 mcg |
| CJC half in vendor writing | 100-200 mcg per injection for the version without DAC |
| Ipamorelin half in vendor writing | 200-300 mcg per injection, two or three times a day |
| Timing | On an empty stomach, roughly two hours after food; the evening dose is the common placement |
| Reported block length | 12-16 weeks followed by four weeks off, taken from the ipamorelin protocol rather than from the blend |
| Female | The source list offers no female amounts for the blend, so the row is left blank |
| Half-lives for planning | About 30 minutes for the CJC half after subcutaneous dosing and about 2 hours for ipamorelin |
Stability follows the peptide rulebook: keep the lyophilisate cold and dark between 2 and 8 C, use a freezer when the vial will sit for a long time, and treat a dissolved solution as a short-lived item. Vendor writing allows roughly four weeks in the fridge, which is convention rather than a labelled figure for this vial, and freezing a mixed solution is never advised.
GH-Axis Combinations
The three arrangements below are research layouts from vendor and forum writing. None was tested as a combination, and the fixed blend itself has no published human study.
What to Expect
- Weeks 1-3. Better sleep and easier recovery are the changes reports mention first. These are user accounts, not measurements.
- Within an hour of a dose. Growth hormone release is the pharmacological event, but the felt effect arrives slowly, which is why the blend is judged over months.
- Months, not weeks. Body-composition changes accumulate over the 12-16 week block rather than inside a short cycle.
- Injection frequency is the constraint. With halves of 30 minutes and 2 hours, two or three daily doses are needed to keep a signal running; a single shot cannot.
- Empty stomach matters. Food blunts the growth hormone response, so timing around meals is part of the method rather than a preference.
- Class side effects. Fluid retention, joint aches and muscle aches are described for growth hormone peptides, particularly when amounts climb.
- Limit. No peer-reviewed human dose exists for athletic use of this mixture, and both halves are prohibited in sport.
Side Effects and Management
Most of the tolerability information belongs to the growth hormone peptide class rather than to this specific vial, and the sources say so.
Pulse Monitoring and No PCT
The blend works through the growth hormone axis and leaves the gonadal axis untouched, so a SERM restart has no role here. Monitoring is about the pulse profile, the sugar level and the clock between blocks.
